300294 博雅生物
已收盘 08-23 15:00:00
资讯
新帖
简况
博雅生物(300294)2024年中报简析:净利润减3.05%,盈利能力上升
证券之星 · 06:12
博雅生物(300294)2024年中报简析:净利润减3.05%,盈利能力上升
国金证券:给予博雅生物买入评级
证券之星 · 08-24 23:30
国金证券:给予博雅生物买入评级
博雅生物获得实用新型专利授权:“一种血浆转移临时存储设备”
证券之星 · 08-24 02:36
博雅生物获得实用新型专利授权:“一种血浆转移临时存储设备”
博雅生物获得实用新型专利授权:“一种血浆袋运输防破裂结构”
证券之星 · 08-24 02:30
博雅生物获得实用新型专利授权:“一种血浆袋运输防破裂结构”
华润医药(03320):博雅生物上半年净利润3.16亿元 同比下降3.05%
智通财经 · 08-23 17:36
华润医药(03320):博雅生物上半年净利润3.16亿元 同比下降3.05%
图解博雅生物中报:第二季度单季净利润同比增5.36%
证券之星 · 08-23 17:18
图解博雅生物中报:第二季度单季净利润同比增5.36%
博雅生物(300294.SZ)发布上半年业绩,净利润3.16亿元,下降3.05%
智通财经 · 08-23 16:58
博雅生物(300294.SZ)发布上半年业绩,净利润3.16亿元,下降3.05%
博雅生物(300294)8月20日股东户数1.68万户,较上期增加0.13%
证券之星 · 08-21
博雅生物(300294)8月20日股东户数1.68万户,较上期增加0.13%
博雅生物(300294.SZ):卡前列素氨丁三醇注射液获药品注册证书
智通财经 · 08-13
博雅生物(300294.SZ):卡前列素氨丁三醇注射液获药品注册证书
肝素概念盘中拉升,博雅生物涨0.36%
自选股智能写手 · 08-13
肝素概念盘中拉升,博雅生物涨0.36%
博雅生物:关于公司监事会主席辞职的公告
智能小浪 · 08-09
博雅生物:关于公司监事会主席辞职的公告
中际旭创、生益电子、博雅生物:7月公募调研次数增至4819次,覆盖496家上市公司
和讯网 · 08-02
中际旭创、生益电子、博雅生物:7月公募调研次数增至4819次,覆盖496家上市公司
【7月公募调研积极性明显提升 电子、机械设备等受关注】统计数据显示,截至7月31日,7月份一共有144家公募进行了上市公司调研,合计调研4819次,调研覆盖496家上市公司。
智通财经 · 08-01
【7月公募调研积极性明显提升 电子、机械设备等受关注】统计数据显示,截至7月31日,7月份一共有144家公募进行了上市公司调研,合计调研4819次,调研覆盖496家上市公司。
7月31日博雅生物涨6.76%,南方医药保健灵活配置混合A基金重仓该股
证券之星 · 07-31
7月31日博雅生物涨6.76%,南方医药保健灵活配置混合A基金重仓该股
博雅生物涨6.76%,国金证券一周前给出“买入”评级
证券之星 · 07-31
博雅生物涨6.76%,国金证券一周前给出“买入”评级
7月30日华润博雅生物乐平单采血浆站正式运营。乐平单采血浆站的正式运营标志着华润博雅生物旗下正式执业运营的单采血浆站数量达到16家。
智通财经 · 07-30
7月30日华润博雅生物乐平单采血浆站正式运营。乐平单采血浆站的正式运营标志着华润博雅生物旗下正式执业运营的单采血浆站数量达到16家。
生物制品行业盘中拉升,博雅生物涨1.98%
自选股智能写手 · 07-29
生物制品行业盘中拉升,博雅生物涨1.98%
血液制品概念盘中拉升,博雅生物涨1.41%
自选股智能写手 · 07-29
血液制品概念盘中拉升,博雅生物涨1.41%
博雅生物被“华润系”接盘后增长不及预期?业绩在变差 高价 “血拼”亏损标的“抢收”
新浪证券 · 07-26
博雅生物被“华润系”接盘后增长不及预期?业绩在变差 高价 “血拼”亏损标的“抢收”
博雅生物(300294)7月24日主力资金净卖出2965.79万元
证券之星 · 07-25
博雅生物(300294)7月24日主力资金净卖出2965.79万元
暂无数据
公司概况
公司名称:
华润博雅生物制药集团股份有限公司
所属行业:
医药制造业
上市日期:
2012-03-08
主营业务:
华润博雅生物制药集团股份有限公司的主营业务以血液制品为主,集生化药、化学药、原料药为辅。公司的主要产品为血液制品业务、天安药业的糖尿病用药业务、新百药业的生化类用药业务、博雅欣和化学药业务、复大医药经销业务。公司是全国较早通过国家药品新版GMP认证的企业之一,公司生产线采用过程自动控制系统对生产过程进行控制,实现了全程CIP、SIP及关键参数的自动记录。公司严格按国家相关规定组织生产和质量控制,大大提高了产品安全性、质量可控性,产品质量指标高于国家标准。
发行价格:
25.00
{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":31.6,"timestamp":1724396616000,"preClose":32,"halted":0,"volume":1760200,"delay":0,"floatShares":426000000,"shares":504000000,"eps":0.4513,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.4,"latestTime":"08-23 15:00:00","open":31.73,"high":32.16,"low":31.39,"amount":55745300,"amplitude":0.0241,"askPrice":31.6,"askSize":8,"bidPrice":31.58,"bidSize":9,"shortable":0,"etf":0,"ttmEps":0.4513,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"adjPreClose":32,"symbolType":"stock","openAndCloseTimeList":[[1724376600000,1724383800000],[1724389200000,1724396400000]],"highLimit":35.2,"lowLimit":28.8,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"pbRate":2.16,"roa":"--","roe":"2.06%","epsLYR":0.47,"committee":-0.37931,"marketValue":15934000000,"floatMarketCap":13460000000,"peRate":70.019943,"changeRate":-0.0125,"turnoverRate":0.0041,"status":1},"requestUrl":"/m/hq/s/300294/tweets","defaultTab":"tweets","newsList":[{"id":"2462693089","title":"博雅生物(300294)2024年中报简析:净利润减3.05%,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2462693089","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462693089?lang=zh_cn&edition=full","pubTime":"2024-08-25 06:12","pubTimestamp":1724537536,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期博雅生物发布2024年中报。截至本报告期末,公司营业总收入8.96亿元,同比下降41.87%,归母净利润3.16亿元,同比下降3.05%。按单季度数据看,第二季度营业总收入4.47亿元,同比下降39.14%,第二季度归母净利润1.64亿元,同比上升5.36%。本报告期博雅生物盈利能力上升,毛利率同比增幅34.34%,净利率同比增幅63.27%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082500000827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"gpt_icon":0},{"id":"2461651806","title":"国金证券:给予博雅生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2461651806","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461651806?lang=zh_cn&edition=full","pubTime":"2024-08-24 23:30","pubTimestamp":1724513437,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司袁维近期对博雅生物进行研究并发布了研究报告《血制品实现稳定增长,静待浆源拓展落地》,本报告对博雅生物给出买入评级,当前股价为31.6元。维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有14家机构给出评级,买入评级14家;过去90天内机构目标均价为36.46。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082400010366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"gpt_icon":0},{"id":"2461454138","title":"博雅生物获得实用新型专利授权:“一种血浆转移临时存储设备”","url":"https://stock-news.laohu8.com/highlight/detail?id=2461454138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461454138?lang=zh_cn&edition=full","pubTime":"2024-08-24 02:36","pubTimestamp":1724438198,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示博雅生物新获得一项实用新型专利授权,专利名为“一种血浆转移临时存储设备”,专利申请号为CN202323572070.8,授权日为2024年8月23日。今年以来博雅生物新获得专利授权4个,较去年同期增加了300%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082400003552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0197","BK0046"],"gpt_icon":0},{"id":"2461492635","title":"博雅生物获得实用新型专利授权:“一种血浆袋运输防破裂结构”","url":"https://stock-news.laohu8.com/highlight/detail?id=2461492635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461492635?lang=zh_cn&edition=full","pubTime":"2024-08-24 02:30","pubTimestamp":1724437835,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示博雅生物新获得一项实用新型专利授权,专利名为“一种血浆袋运输防破裂结构”,专利申请号为CN202323594574.X,授权日为2024年8月23日。今年以来博雅生物新获得专利授权4个,较去年同期增加了300%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082400002534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300294","BK0046"],"gpt_icon":0},{"id":"2461455024","title":"华润医药(03320):博雅生物上半年净利润3.16亿元 同比下降3.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461455024","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461455024?lang=zh_cn&edition=full","pubTime":"2024-08-23 17:36","pubTimestamp":1724405793,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华润医药(03320)发布公告,该公司附属华润博雅生物截至2024年6月30日止6个月实现营业收入8.96亿元,同比下降41.87%。实现归属于上市公司股东的净利润3.16亿元,同比下降3.05%。实现归属于上市公司股东的扣除非经常性损益的净利润2.59亿元,同比增长0.57%。基本每股收益0.63元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1169444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03320","300294"],"gpt_icon":0},{"id":"2461571445","title":"图解博雅生物中报:第二季度单季净利润同比增5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461571445","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461571445?lang=zh_cn&edition=full","pubTime":"2024-08-23 17:18","pubTimestamp":1724404714,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物2024年中报显示,公司主营收入8.96亿元,同比下降41.87%;归母净利润3.16亿元,同比下降3.05%;扣非净利润2.59亿元,同比上升0.57%;其中2024年第二季度,公司单季度主营收入4.47亿元,同比下降39.14%;单季度归母净利润1.64亿元,同比上升5.36%;单季度扣非净利润1.32亿元,同比上升10.02%;负债率6.71%,投资收益670.98万元,财务费用-1704.38万元,毛利率67.03%。财报数据概要请见下图: 以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300032119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"gpt_icon":0},{"id":"2461554220","title":"博雅生物(300294.SZ)发布上半年业绩,净利润3.16亿元,下降3.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461554220","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461554220?lang=zh_cn&edition=full","pubTime":"2024-08-23 16:58","pubTimestamp":1724403505,"startTime":"0","endTime":"0","summary":"智通财经APP讯,博雅生物 发布2024年半年度报告,报告期内,公司实现营业收入8.96亿元,同比下降41.87%。实现归属于上市公司股东的净利润3.16亿元,同比下降3.05%。基本每股收益0.63元。报告期内,在医药行业深化整治的宏观背景下,公司积极应对,多维度推动业务发展,保障内生增长动力。公司聚焦于血液制品核心战略,通过优化血浆资源配置与业务结构调整,显著提升了采浆量、管理水平及服务质量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1169366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300294"],"gpt_icon":0},{"id":"2461812393","title":"博雅生物(300294)8月20日股东户数1.68万户,较上期增加0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461812393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461812393?lang=zh_cn&edition=full","pubTime":"2024-08-21 17:03","pubTimestamp":1724230998,"startTime":"0","endTime":"0","summary":"证券之星消息,近日博雅生物披露,截至2024年8月20日公司股东户数为1.68万户,较8月9日增加21.0户,增幅为0.13%。在生物制品行业个股中,博雅生物股东户数低于行业平均水平,截至8月20日,生物制品行业平均股东户数为3.38万户。从股价来看,2024年8月9日至2024年8月20日,博雅生物区间跌幅为2.84%,在此期间股东户数增加21.0户,增幅为0.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100030189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0046","300294"],"gpt_icon":0},{"id":"2459927623","title":"博雅生物(300294.SZ):卡前列素氨丁三醇注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2459927623","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459927623?lang=zh_cn&edition=full","pubTime":"2024-08-13 17:53","pubTimestamp":1723542795,"startTime":"0","endTime":"0","summary":"智通财经APP讯,博雅生物(300294.SZ)公告,公司全资子公司南京新百药业有限公司(简称:新百药业)于今日收到国家药品监督管理局核准签发的卡前列素氨丁三醇注射液《药品注册证书》。据悉,卡前列素氨丁三醇注射液适用于妊娠期为13至20周的流产,以及与中期流产有关的情况,同时适用于常规处理方法无效的子宫收缩弛缓引起的产后出血现象。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1163565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0197","300294","BK0046","BK0239"],"gpt_icon":0},{"id":"2459699446","title":"肝素概念盘中拉升,博雅生物涨0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459699446","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459699446?lang=zh_cn&edition=full","pubTime":"2024-08-13 09:53","pubTimestamp":1723513988,"startTime":"0","endTime":"0","summary":"08月13日,肝素概念盘中拉升,截至09点53分,肝素概念整体指数上涨0.67%,报713.110点。从个股上来看,该概念的成分股中,博雅生物涨0.36%,辰欣药业、千红制药涨幅居前。从资金上来看,截止发稿,肝素概念主力净流入为-4051.32万,其中辰欣药业受到资金热捧,主力净流入362.23万;拉长时间线来看,该板块近20日主力资金净流入-7.03亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813095308aefe8572&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813095308aefe8572&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["300294","BK0239","603367","BK0197","BK0046"],"gpt_icon":0},{"id":"2458438557","title":"博雅生物:关于公司监事会主席辞职的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2458438557","media":"智能小浪","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458438557?lang=zh_cn&edition=full","pubTime":"2024-08-09 18:00","pubTimestamp":1723197600,"startTime":"0","endTime":"0","summary":"华润博雅生物制药集团股份有限公司关于公司监事会主席辞职的公告华润博雅生物制药集团股份有限公司监事会于2024年8月9日收到公司监事会主席唐娜女士递交的书面《辞职报告》,唐娜女士因工作调动申请辞去公司第八届监事会监事、监事会主席职务,辞职后将不再担任公司任何职务。截至本公告披露日,唐娜女士未持有公司股份。公司监事会对唐娜女士在任职期间为公司发展做出的努力和贡献表示衷心感谢!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-08-09/doc-inchzyae5620730.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-08-09/doc-inchzyae5620730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0197","300294","BK0046"],"gpt_icon":0},{"id":"2456416618","title":"中际旭创、生益电子、博雅生物:7月公募调研次数增至4819次,覆盖496家上市公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2456416618","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456416618?lang=zh_cn&edition=full","pubTime":"2024-08-02 09:18","pubTimestamp":1722561525,"startTime":"0","endTime":"0","summary":"快讯正文【7月公募机构调研活跃,调研次数和覆盖公司数量双增长】7月份,共有144家公募机构参与了对上市公司的调研活动,总计进行了4819次调研,涉及496家上市公司。与6月份相比,参与调研的公募机构数量增加了5.11%,调研次数增长了18.05%。在众多被调研的上市公司中,中际旭创、生益电子和博雅生物最受公募机构关注。此外,电子、机械设备、医药生物、计算机和基础化工这五个行业在7月份各有超过30家上市公司接受了公募机构的调研,其中电子行业有90家,机械设备行业有75家,医药生物行业有55家,计算机行业有40家,基础化工行业有33家。下载和讯APP查看快讯,体验更佳>>","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408020926279f06fcc4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408020926279f06fcc4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306685.HKD","BK0070","LU0531971595.HKD","LU2580892862.HKD","688183","LU0871576103.HKD","LU1770034418.SGD","BK0167","LU0164865239.USD","BK0077","LU1251922891.USD","300294","BK0046","BK0214","HK0000320223.HKD","LU1997245177.USD","LU1303224171.USD","LU1997245094.SGD","LU1719994722.HKD","HK0000320264.USD","BK0239","SG9999011746.SGD","SGXZ49509284.SGD","BK0028","LU1655091616.SGD","BK0197","300308","HK0000306701.USD","LU0039217434.USD","LU2580892789.USD","SGXZ81163826.USD"],"gpt_icon":0},{"id":"2456053061","title":"【7月公募调研积极性明显提升 电子、机械设备等受关注】统计数据显示,截至7月31日,7月份一共有144家公募进行了上市公司调研,合计调研4819次,调研覆盖496家上市公司。","url":"https://stock-news.laohu8.com/highlight/detail?id=2456053061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456053061?lang=zh_cn&edition=full","pubTime":"2024-08-01 17:34","pubTimestamp":1722504895,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2580892789.USD","163118","LU0871576103.HKD","BK0197","LU1251922891.USD","SGXZ49509284.SGD","000808.SH","LU1997245094.SGD","LU1655091616.SGD","BK0070","300294","LU2580892862.HKD","BK0214","LU0531971595.HKD","SGXZ81163826.USD","BK0028","HK0000306701.USD","HK0000320264.USD","LU1303224171.USD","BK0239","LU0039217434.USD","300308","688183","LU1997245177.USD","HK0000306685.HKD","LU1719994722.HKD","HK0000320223.HKD","BK0167","SG9999011746.SGD","BK0077","BK0046","LU1770034418.SGD","LU0164865239.USD","159998"],"gpt_icon":0},{"id":"2455906251","title":"7月31日博雅生物涨6.76%,南方医药保健灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2455906251","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455906251?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:46","pubTimestamp":1722415619,"startTime":"0","endTime":"0","summary":"证券之星消息,7月31日博雅生物涨6.76%,收盘报31.73元,换手率1.59%,成交量6.76万手,成交额2.1亿元。重仓博雅生物的前十大公募基金请见下表:该股最近90天内共有14家机构给出评级,买入评级14家;过去90天内机构目标均价为38.69。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共25家,其中持有数量最多的公募基金为南方医药保健灵活配置混合A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300294"],"gpt_icon":0},{"id":"2455906269","title":"博雅生物涨6.76%,国金证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2455906269","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455906269?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:46","pubTimestamp":1722415611,"startTime":"0","endTime":"0","summary":"今日博雅生物涨6.76%,收盘报31.73元。2024年7月18日,国金证券研究员袁维发布了对博雅生物的研报《收购绿十字(中国),新增浆站有望贡献业绩弹性》,该研报对博雅生物给出“买入”评级。维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为40.33%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为东方财富证券的何玮。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"gpt_icon":0},{"id":"2455755996","title":"7月30日华润博雅生物乐平单采血浆站正式运营。乐平单采血浆站的正式运营标志着华润博雅生物旗下正式执业运营的单采血浆站数量达到16家。","url":"https://stock-news.laohu8.com/highlight/detail?id=2455755996","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455755996?lang=zh_cn&edition=full","pubTime":"2024-07-30 12:54","pubTimestamp":1722315292,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0197","BK0046","BK0239","300294"],"gpt_icon":0},{"id":"2455505310","title":"生物制品行业盘中拉升,博雅生物涨1.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2455505310","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455505310?lang=zh_cn&edition=full","pubTime":"2024-07-29 10:09","pubTimestamp":1722218981,"startTime":"0","endTime":"0","summary":"07月29日,生物制品行业盘中拉升,截至10点09分,生物制品行业整体指数上涨0.54%,报5596.220点。从个股上来看,该行业的成分股中,博雅生物涨1.98%,康为世纪、天坛生物、君实生物-U涨幅居前。从资金上来看,截止发稿,生物制品行业主力净流入为-4156.45万,其中君实生物-U受到资金热捧,主力净流入955.79万;拉长时间线来看,该板块近20日主力资金净流入-22.70亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240729100941968210dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240729100941968210dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0197","688180","300294","BK0046","BK0239"],"gpt_icon":0},{"id":"2455503480","title":"血液制品概念盘中拉升,博雅生物涨1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2455503480","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455503480?lang=zh_cn&edition=full","pubTime":"2024-07-29 09:54","pubTimestamp":1722218047,"startTime":"0","endTime":"0","summary":"07月29日,血液制品概念盘中拉升,截至09点54分,血液制品概念整体指数上涨0.54%,报704.930点。从个股上来看,该概念的成分股中,博雅生物涨1.41%,同方股份、天坛生物、上海莱士涨幅居前。从资金上来看,截止发稿,血液制品概念概念主力净流入为-728.56万,其中同方股份受到资金热捧,主力净流入200.50万;拉长时间线来看,该板块近20日主力资金净流入-7.93亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240729095407941fb59a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240729095407941fb59a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0067","600100","BK0101","BK0012","BK0122","BK0043","300294","BK0046","BK0214","BK0026","BK0030","BK0188","BK0045","BK0038","BK0239","BK0028","BK0197","BK0124","BK0041","BK0196"],"gpt_icon":0},{"id":"2454397342","title":"博雅生物被“华润系”接盘后增长不及预期?业绩在变差 高价 “血拼”亏损标的“抢收”","url":"https://stock-news.laohu8.com/highlight/detail?id=2454397342","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454397342?lang=zh_cn&edition=full","pubTime":"2024-07-26 16:24","pubTimestamp":1721982240,"startTime":"0","endTime":"0","summary":"这是否是博雅生物不惜耗巨资高溢价收购亏损资产原因之一?此外,博雅生物关联股东体外资产注入上市公司体内市场呼声不断。 近日,博雅生物发布公告,拟斥资逾18亿元并购一家血液制品公司,以加码采血浆站布局。 目前,市场对博雅生物注入关联资产丹霞生物存预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/observe/2024-07-26/doc-incfmyaa2043365.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-07-26/doc-incfmyaa2043365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0239","BK0197","300294"],"gpt_icon":0},{"id":"2454864415","title":"博雅生物(300294)7月24日主力资金净卖出2965.79万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454864415","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454864415?lang=zh_cn&edition=full","pubTime":"2024-07-25 09:23","pubTimestamp":1721870610,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月24日收盘,博雅生物报收于31.69元,下跌3.74%,换手率1.27%,成交量5.42万手,成交额1.74亿元。7月24日的资金流向数据方面,主力资金净流出2965.79万元,占总成交额17.08%,游资资金净流入1331.57万元,占总成交额7.67%,散户资金净流入1634.23万元,占总成交额9.41%。近5日资金流向一览见下表:博雅生物融资融券信息显示,融资方面,当日融资买入1245.27万元,融资偿还1044.5万元,融资净买入200.77万元。博雅生物主营业务:血液制品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072500014836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300294"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业园区惠泉路333号","stockEarnings":[{"period":"1week","weight":-0.0539},{"period":"1month","weight":-0.0028},{"period":"3month","weight":-0.031},{"period":"6month","weight":0.1318},{"period":"1year","weight":0.06},{"period":"ytd","weight":-0.0526}],"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","perCapita":"25347股","boardName":"医药制造业","registeredCapital":"50424万元","compareEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0164},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0501},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0405}],"survey":" 华润博雅生物制药集团股份有限公司的主营业务以血液制品为主,集生化药、化学药、原料药为辅。公司的主要产品为血液制品业务、天安药业的糖尿病用药业务、新百药业的生化类用药业务、博雅欣和化学药业务、复大医药经销业务。公司是全国较早通过国家药品新版GMP认证的企业之一,公司生产线采用过程自动控制系统对生产过程进行控制,实现了全程CIP、SIP及关键参数的自动记录。公司严格按国家相关规定组织生产和质量控制,大大提高了产品安全性、质量可控性,产品质量指标高于国家标准。","serverTime":1724567063157,"listedPrice":25,"stockholders":"16804人(较上一季度增加0.13%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}